Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Healthcare Stocks Got Crushed After the Election - Is It Time to Buy Eli Lilly?

November 28, 2024
Eli Lilly and Company (LLY) shares have seen a significant dip after the recent election, along with other healthcare stocks. However, experts are now considering whether it is a good time to buy the dip in Eli Lilly stock.
The election results brought uncertainty to the healthcare industry, particularly regarding the future of drug prices and policy changes. This uncertainty caused a sell-off in healthcare stocks, including Eli Lilly.
Despite the recent dip, some analysts believe that this could present a buying opportunity for investors. Eli Lilly is a leading pharmaceutical company that has shown strong performance and innovation in recent years. They have a diverse portfolio of drugs for various therapeutic areas, including diabetes, oncology, and immunology.
Furthermore, Eli Lilly has been focusing on expanding its pipeline of new drugs through strategic acquisitions and collaborations. This approach has proven successful in driving revenue growth and maintaining a competitive edge in the market.
Experts are also optimistic about the potential growth in Eli Lilly's diabetes drug portfolio. With President Biden's plans to expand coverage of weight-loss drugs, it could boost the demand for Eli Lilly's diabetes drugs such as Trulicity.
However, it is essential for investors to seek professional advice before making any investment decisions. Stocks Prognosis, a reputable investment advisory service, provides expert predictions on the movement of stocks like Eli Lilly. Their insights and recommendations can help investors make informed choices.
In conclusion, while healthcare stocks, including Eli Lilly, have experienced a dip after the election, some experts believe it may be a good time to consider buying Eli Lilly stock. The company's strong performance, innovation, and focus on strategic acquisitions make it an attractive investment opportunity. Investors are encouraged to consult professionals like Stocks Prognosis to get a reliable forecast on the future movement of Eli Lilly stock.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYAugust 12, 2025Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results  ~1 min.

Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower....


LLYAugust 8, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast with Profit of 18.31%  ~1 min.

ELI LILLY AND COMPANY stock has successfully achieved the price target forecast set by QuantWave with a profit of 18.31%. The forecast, which indicated a short position on June 4, 2025, at a price of 764....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 20.09% Profit: QuantWave Achieves Success  ~1 min.

On January 28, 2025, QuantWave, an automated forecasting platform, issued a short signal for ELI LILLY AND COMPANY stock when it was trading at 800.2 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits QuantWave Forecast, Delivering 19.57% Profit  ~1 min.

ELI LILLY AND COMPANY has achieved the price target forecast set by QuantWave, signaling a 19.57% profit for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast as QuantWave Users Gain 17.38% Profit  ~1 min.

ELI LILLY AND COMPANY stock recently achieved the price target forecast set by QuantWave, marking a significant success for users of the automated forecasting platform....


LLYAugust 7, 2025ELI LILLY AND COMPANY Hits Forecast Profit of 23.55%: A Success Story for QuantWave  ~2 min.

ELI LILLY AND COMPANY, a prominent player in the pharmaceutical industry, recently achieved a significant milestone by hitting a price target forecast generated by the innovative forecasting platform, QuantWave. The forecast, which indicated a short direction signal on April 17, 2025, at a price of 836.4 USD, proved to be accurate as the stock reached the predicted target price of 639.46 USD on Au...


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecast Price Target with 22.13% Profit - QuantWave Achieves Success in Stock Prediction  ~2 min.

ELI LILLY AND COMPANY stock recently reached the forecast price target set by QuantWave, resulting in a profit of 22.13%....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast, Generating 17.25% Profit  ~1 min.

ELI LILLY AND COMPANY stock has successfully achieved the price target forecast set by QuantWave, reaching a profit of 17.25%. The forecast signal was issued on April 30, 2024, with the stock price at $772....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Short Price Target Forecast with 19.15% Profit  ~1 min.

On December 24, 2024, QuantWave, the automated forecasting platform, issued a short signal for ELI LILLY AND COMPANY stock when it was priced at 790.94 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast with 22.51% Profit for QuantWave Users  ~2 min.

ELI LILLY AND COMPANY, a prominent pharmaceutical company, recently achieved the price target forecast set by QuantWave, an automated forecasting platform, resulting in a profitable outcome for investors. The forecast signal was generated on 8th November 2024 when the stock was priced at 825.23 $. The prediction indicated a short direction, and on 7th August 2025, the target price of 639.46 $ was ...


GSKJanuary 25, 2025Is GSK plc GSK an Undervalued Defensive Stock for 2025?  ~2 min.

GSK plc (NYSE: GSK) has been gaining attention as a potential undervalued defensive stock for investors looking towards 2025....


ABBVDecember 18, 2024AbbVie Inc. ABBV to Acquire Nimble Therapeutics in a Game-Changing Move  ~1 min.

AbbVie Inc., a leading biopharmaceutical company, has announced its acquisition of Nimble Therapeutics, a pioneer in the field of immunology....


ABBVDecember 17, 2024AbbVie Inc. ABBV to Acquire Nimble Therapeutics, Boosting Immunology Pipeline  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, has recently announced its plan to acquire Nimble Therapeutics, a leading biotechnology company, in a move to strengthen its already robust immunology pipeline....


ABBVDecember 20, 2024AbbVie ABBV to Acquire Nimble Therapeutics Further Strengthening Immunology Pipeline  ~1 min.

AbbVie Inc. (NYSE: ABBV) has announced its plans to acquire Nimble Therapeutics, a biotechnology company specializing in antibody drug discovery....


BIIBDecember 21, 2024Biogen Inc.: A Closer Look at the Healthcare Sector Underperformance  ~2 min.

Biogen Inc., a leading biotechnology company, has been in the spotlight recently due to its underperformance in the healthcare sector....